BR112015008552A2 - material cristalino, composição farmacêutica, e, processo para a preparação de um material cristalino - Google Patents

material cristalino, composição farmacêutica, e, processo para a preparação de um material cristalino

Info

Publication number
BR112015008552A2
BR112015008552A2 BR112015008552A BR112015008552A BR112015008552A2 BR 112015008552 A2 BR112015008552 A2 BR 112015008552A2 BR 112015008552 A BR112015008552 A BR 112015008552A BR 112015008552 A BR112015008552 A BR 112015008552A BR 112015008552 A2 BR112015008552 A2 BR 112015008552A2
Authority
BR
Brazil
Prior art keywords
crystalline material
pharmaceutical composition
crystalline
carboxylic acid
preparation
Prior art date
Application number
BR112015008552A
Other languages
English (en)
Inventor
Hafner Andreas
Salvador Beate
Rödel Eva
Blatter Fritz
Vossen Marcus
Szelagiewicz Martin
Chiodo Tiziana
Hintermann Tobias
Original Assignee
Basf Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Se filed Critical Basf Se
Publication of BR112015008552A2 publication Critical patent/BR112015008552A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C07C65/10—Salicylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1 / 1 resumo “material cristalino, composiã‡ãƒo farmacãšutica, e, processo para a preparaã‡ãƒo de um material cristalino” a presente invenã§ã£o refere-se a materiais cristalinos compreendendo nilotinibe e um ã¡cido carboxã­lico, ã©ster de ã¡cido carboxã­lico, amida de ã¡cido carboxã­lico ou ã¡cido sulfã´nico como um formador de cocristal, e a composiã§ãµes farmacãªuticas que compreendem os referidos materiais. a invenã§ã£o tambã©m se refere a processos para preparar os referidos materiais cristalinos e a mã©todos de utilizaã§ã£o dessas matã©rias cristalinas para o tratamento de uma condiã§ã£o de doenã§a em que a inibiã§ã£o da tirosina quinase ã© benã©fica.
BR112015008552A 2012-10-19 2013-10-16 material cristalino, composição farmacêutica, e, processo para a preparação de um material cristalino BR112015008552A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261715865P 2012-10-19 2012-10-19
EP12189264 2012-10-19
EP13167657 2013-05-14
PCT/EP2013/071580 WO2014060449A1 (en) 2012-10-19 2013-10-16 Multicomponent crystalline system comprising nilotinib and selected co-crystal formers

Publications (1)

Publication Number Publication Date
BR112015008552A2 true BR112015008552A2 (pt) 2017-07-04

Family

ID=50487597

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015008552A BR112015008552A2 (pt) 2012-10-19 2013-10-16 material cristalino, composição farmacêutica, e, processo para a preparação de um material cristalino

Country Status (11)

Country Link
US (1) US9567317B2 (pt)
EP (1) EP2909191B1 (pt)
JP (2) JP2015534967A (pt)
KR (1) KR20150068483A (pt)
CN (1) CN104736531A (pt)
AU (1) AU2013333953B2 (pt)
BR (1) BR112015008552A2 (pt)
CA (1) CA2887540A1 (pt)
MX (1) MX2015004947A (pt)
RU (1) RU2652121C2 (pt)
WO (1) WO2014060449A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013510113A (ja) 2009-11-06 2013-03-21 ビーエーエスエフ ソシエタス・ヨーロピア ４−ヒドロキシ安息香酸及び選択された殺有害生物剤の結晶複合体
WO2013189910A1 (en) 2012-06-22 2013-12-27 Basf Se Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
US9290452B2 (en) 2012-08-06 2016-03-22 Basf Se Multicomponent crystalline system comprising deferasirox and isonicotinamide and a process for the preparation thereof
CN105377842A (zh) 2013-07-25 2016-03-02 巴斯夫欧洲公司 呈无定形形式的达沙替尼的盐
CA2917183C (en) 2013-07-25 2019-01-29 Basf Se Salts of dasatinib in crystalline form
DK3166932T3 (en) 2014-07-08 2018-10-01 Basf Agro Bv PROCEDURE FOR PREPARING SUBSTITUTED OXIRANES AND TRIAZOLES
CA2964198C (en) 2014-10-16 2023-03-14 Apotex Inc. Solid forms of nilotinib hydrochloride
US9603937B2 (en) * 2015-03-09 2017-03-28 Theaprin Pharmaceuticals Inc. Platform drug delivery system utilizing crystal engineering and theanine dissolution
WO2016180642A1 (en) 2015-05-08 2016-11-17 BASF Agro B.V. A process for the preparation of terpinolene epoxide
DK3294700T3 (da) 2015-05-08 2020-04-14 Basf Agro Bv Fremgangsmåde til fremstilling af limonen-4-ol
ES2814499T3 (es) * 2016-03-14 2021-03-29 Pliva Hrvatska D O O Formas en estado sólido de sales de Nilotinib
DK3472138T3 (da) 2016-06-15 2020-11-23 Basf Agro Bv Fremgangsmåde til epoxidering af en tetrasubstitueret alken
KR20190017926A (ko) 2016-06-15 2019-02-20 바스프 아그로 비.브이. 사치환된 알켄의 에폭시화 방법
AU2019285066B2 (en) 2018-06-15 2024-06-13 Handa Pharmaceuticals, Inc. Kinase inhibitor salts and compositions thereof
CN113402575B (zh) * 2021-06-18 2022-04-22 邦泰生物工程(深圳)有限公司 一种制备烟酰胺单核苷酸共晶体的方法
AU2022292092A1 (en) 2021-06-19 2024-02-01 Helm Ag Granulate composition comprising nilotinib

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
EP1596869B1 (en) 2003-01-21 2014-06-04 New Form Pharmaceuticals Inc. Novel cocrystallization
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
EP2262793B1 (en) 2008-11-05 2012-10-03 Teva Pharmaceutical Industries Ltd. Nilotinib hci crystalline forms
CZ20098A3 (cs) * 2009-01-13 2010-07-21 Zentiva, K.S. Lékové formy inhibitoru tyrosinových kináz
WO2011086541A1 (en) 2010-01-15 2011-07-21 Generics [Uk] Limited Novel polymorph of nilotinib monohydrochloride monohydrate
JP5894153B2 (ja) 2010-06-21 2016-03-23 テバ ファーマシューティカル インダストリーズ リミティド ニロチニブ塩及びそれらの結晶性形態
CN102453024B (zh) * 2010-10-27 2014-09-03 浙江九洲药业股份有限公司 一种尼罗替尼盐酸盐晶型及其制备方法
US9249108B2 (en) 2010-11-22 2016-02-02 Basf Se Multicomponent system of rosuvastatin calcium salt and sorbitol
WO2012143308A1 (en) 2011-04-18 2012-10-26 Basf Se Multicomponent crystalline system of rosuvastatin calcium salt and vanillin
CA2841655A1 (en) 2011-07-26 2013-01-31 Basf Se Multicomponent crystalline system of ezetimibe and proline
MX2014002068A (es) 2011-08-30 2014-05-30 Basf Se Co - cristales de ciprodinilo y ditianon.
US20150087657A1 (en) 2011-12-06 2015-03-26 Basf Se Multicomponent crystalline system of voriconazole with fumaric acid
BR112014016137B1 (pt) 2011-12-30 2021-02-09 Basf Se forma cristalina não solvatada, monossolvato de tolueno cristalino, solvato de acetona cristalino, composição, processo para a preparação do monossolvato de tolueno cristalino, processo para a preparação de uma forma cristalina não solvatada, processo para a preparação do solvato de acetona cristalino, método para obter o solvato de acetona cristalino, uso de uma forma cristalina, e, método para produzir um catalisador de metal de transição
US8796481B2 (en) 2011-12-30 2014-08-05 Basf Se Crystalline solvate and non-solvated forms of 6,6′-[[3,3′,5,5′-tetrakis(1,1-dimethylethyl)-[1,1′biphenyl]-2,2′-diyl]bis(oxy)]bis-dibenzo [d,f] [1,3,2]-dioxaphosphepine
WO2013143927A1 (en) 2012-03-29 2013-10-03 Basf Se Co-crystals of dicamba and a co-crystal former b
CN104334549B (zh) 2012-05-25 2017-03-22 巴斯夫欧洲公司 1,5‑二甲基‑6‑硫代‑3‑(2,2,7‑三氟‑3‑氧代‑4‑(丙‑2‑炔基)‑3,4‑二氢‑2H‑苯并[b][1,4]噁嗪‑6‑基)‑1,3,5‑三嗪烷‑2,4‑二酮的晶型A
WO2013174694A1 (en) 2012-05-25 2013-11-28 Basf Se Crystalline form b of 1,5-dimethyl-6-thioxo-3-(2,2,7-trifluoro-3-oxo-4-(prop-2-ynyl)-3,4-dihydro-2h-benzo[b][1,4]oxazin-6-yl)-1,3,5-triazinane-2,4-dione
ES2637829T3 (es) 2012-06-15 2017-10-17 Basf Se Cristales multicomponentes que comprenden dasatinib y agentes de formación de cocristales seleccionados
WO2013189910A1 (en) 2012-06-22 2013-12-27 Basf Se Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
US9290452B2 (en) 2012-08-06 2016-03-22 Basf Se Multicomponent crystalline system comprising deferasirox and isonicotinamide and a process for the preparation thereof

Also Published As

Publication number Publication date
RU2652121C2 (ru) 2018-04-25
AU2013333953B2 (en) 2017-08-31
US20150246901A1 (en) 2015-09-03
EP2909191A1 (en) 2015-08-26
WO2014060449A1 (en) 2014-04-24
KR20150068483A (ko) 2015-06-19
JP2015534967A (ja) 2015-12-07
CN104736531A (zh) 2015-06-24
EP2909191B1 (en) 2019-03-20
US9567317B2 (en) 2017-02-14
AU2013333953A1 (en) 2015-04-30
JP2018065876A (ja) 2018-04-26
CA2887540A1 (en) 2014-04-24
RU2015118436A (ru) 2016-12-10
MX2015004947A (es) 2016-02-22

Similar Documents

Publication Publication Date Title
BR112015008552A2 (pt) material cristalino, composição farmacêutica, e, processo para a preparação de um material cristalino
BR112012016879A2 (pt) Derivados de fumarato de acido graxo e seus usos
BR112017023764A2 (pt) derivados de ciclohexano substituído por amido
BR112014008045A2 (pt) benzilindazóis substituídos para uso como inibidores de bub1 cinase no tratamento de doenças hiperproliferativas
BR112015009376A2 (pt) ácidos indaniloxidihidrobenzofuranilacéticos
ECSP13012668A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
BR112014010183B8 (pt) Composto, composição farmacêutica, produto, e, uso de um composto
BR112013023517A2 (pt) "inibidores de produção de leucotrieno, seus usos, e composição farmacêutica"
BR112012027509A8 (pt) Composto pirazolil-quinoxalina inibidor de quinase, combinação, produto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e método
BR112013021537A2 (pt) derivados de tiazolilpenil-benzenosulfonamido como inibidores da quinase
BR112013018515A2 (pt) derivados de pirrol tricíclico, processo para preparação e seu uso como inibidores da quinase
BR112013031268A2 (pt) "polipeptídeos análogos de pramlintida, uso dos mesmos, composição farmacêutica compreendendo os referidos polipeptídeos e método de preparação da referida composição".
BR112012010706A2 (pt) composto, composição farmacêutica, combinação do produto farmacêutico, uso de um composto, e, métodos para o tratamento de uma doença ou condição, e para inibir um bromodomínio
BR112014010576A8 (pt) compostos inibidores de neprilisina (nep), seus usos, processo de preparação dos compostos e composição farmacêutica compreendendo os compostos
CL2015003602A1 (es) Composiciones y métodos para tratar anemia.
BR112012012906A2 (pt) triazolopiridinas
UY33241A (es) ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
CR20130264A (es) Compuestos pirimidinona para uso en el tratamiento de enfermedades o condiciones mediadas por lp-pla2
BR112013005622A2 (pt) heteroaril metil amidas
MX2020005736A (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
BR112014029439A2 (pt) derivados de ácido salicílico, sal farmaceuticamente aceitável dos mesmos, composição dos mesmos e método de uso dos mesmos
BR112013030391A2 (pt) derivados de piperidina 3- espirocíclicos como agonistas dos receptores de grelina
BR112015010271A8 (pt) produto de comicronização, processo para o preparo de um produto de comicronização, composição farmacêutica e seus usos
BR112012022946A2 (pt) método para proliferar cardiomiócitos usando micro-rna
BR112015002429A2 (pt) processo para a preparação de pemetrexede e sal de lisina do mesmo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2599 DE 27-10-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.